Skin Toxicity Ant Anti-EGFR-Therapy: A Mock Trouble for Elderly and Frail Patients with Mcrc

Abstract

prognosis and survival. co morbidity advanced most clinical trials sufficient on the appropriate management of elderly patients with metastatic CRC. The development of new therapeutic agents bevacizumab (anti-VRGF) and cetuximab panitumumab (anti-Epidermal Growth Factor Receptor (EGFR)) which target specific molecular events in tumour cells provides new opportunities to improve the treatment of this type of cancer.